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Abstract
Parkinson’s disease is the second most common neurodegenerative disorder, affecting
nearly 1 million people in the US and it is predicted that the number will keep increasing.
Parkinson’s disease is difficult to diagnose due to its similarity with other diseases that
share the parkinsonian symptoms and the subjectivity of its assessment, thus
increasing the probabilities of misdiagnosis. Therefore, it is relevant to develop
diagnostic tools that are quantitatively based and monitoring tools to improve the
patient’s quality of life. Computer-based assessment systems have shown to be
successful in this field through diverse approaches that can be classified into two main
categories: sensor-based and computer vision-based systems. In this thesis, the
implementation of a computer vision system to detect Parkinson’s disease is explored.
As Parkinson’s diseases has characteristic motor symptoms, and gait is mainly affected,
a computer vision system is proposed to analyze the gait features to classify subjects
with Parkinson’s disease. Using Microsoft’s Kinect sensor and Azure Kinect sensor, the
position of body joints in a 3D space was obtained and angles between those were
calculated. The standard deviation of 7 different angles over time was calculated for
each and used as features in a support vector machine with the purpose of classifying
Parkinson’s disease patients versus controls. Moreover, challenges and future
perspectives for the implementation of computer-vision systems as supportive
diagnostic tools for Parkinson’s disease are discussed.
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Introduction
In the last decade, medicine has evolved exponentially; multiple treatments and
diagnostic tools have been developed for many areas. However, the early diagnosis
and treatment of neurodegenerative diseases has eluded this rapid evolution in
medicine. The complexity and roots of these diseases play an important role in the
difficulty to diagnose and treat them. One disease in particular, Parkinson’s disease,
has a vast impact on patients’ quality of life. Parkinson’s disease affects more than 10
million people worldwide, nearly 1 million people in the US, and it is expected that the
number will keep growing (Marras et al. 2018). Parkinson’s disease is a progressive
parkinsonism due to the loss of dopaminergic neurons in the substantia nigra of the
midbrain without an identifiable cause, and has bradykinesia, resting tremor, rigidity,
postural reflex impairment, shuffling gait and imbalance as motor symptoms (Jellinger
1991; Jankovic and Tolosa 2015; Papadakis 2019). The treatment of Parkinson’s
disease in early stages with cabergoline, a dopamine receptor agonist, has shown a
lower risk and delay of onset motor complications (Rinne et al. 1998). As the treatment
of Parkinson’s disease at early stages has shown a lower risk and delay of onset motor
complications it is relevant to be able to recognize subtle motor problems as early as
possible in the development of the disease. On the other hand, it is estimated that when
motor symptoms appear, already 50% of all dopamine receptors have disappeared
(Marsden 1990; Ross et al. 2004). Therefore, several premotor symptoms have been
proposed for the early diagnosis of Parkinson’s disease (Tolosa et al. 2007, 2009;
Iranzo 2011; Lang 2011); however, the most studied premotor symptoms like olfactory
loss, REM sleeping disorder, constipation and mood changes are not specific enough to
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be used as stand-alone biomarkers to diagnose Parkinson’s disease (Tinelli et al.
2016). As the non-motor motor symptoms are not specific enough to be used as standalone indicators of the development of Parkinson’s disease, and concurrently a powerful
revolution in computer science has taken place in the last decades, the implementation
of computer systems as supportive diagnostic tools has become a growing research
area.
Moreover, an important advantage of the computer-based systems compared to the
traditional scales for Parkinson’s disease diagnosis is their objectivity, as the analysis
performed is quantitative contrasted to the qualitative assessment of traditional scales
that could be confounded by observer bias. As beforementioned, while nonmotor
symptoms are present in all patients, these symptoms are mainly used as supportive
criteria for the diagnosis, as they are not definitive indicators of Parkinson’s disease.
Therefore, it is relevant to focus on the motor symptoms for the implementation of
computer-based systems in the diagnosis and monitoring of Parkinson’s disease.
In this research project, a computationally inexpensive pipeline and programs are
developed in order to classify subjects as Parkinson’s disease patients or controls.
Microsoft Kinect Azure and Microsoft Kinect v2 are used to obtain the 3D position of the
joints, and angles are calculated from those. Posteriorly, a support vector machine is
implemented to classify Parkinson’s patients versus controls using the standard
deviation from the previously calculated angles as features. As one of the key motor
symptoms of Parkinson’s patients is a rigid gait, it would be expected that Parkinson’s
patients’ angles would have a lower standard deviation compared to controls.
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The research question proposed is whether the standard deviation of the angles can be
used as an effective feature for classifying the subjects.
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Chapter I: Background
Pathology and epidemiology of Parkinson’s disease
Parkinson’s disease is the second most common neurodegenerative disorder (Reich
and Savitt 2018) as it affects more than 10 million people worldwide and nearly 1 million
people in the US (Marras et al. 2018). It is important to recognize the difference
between parkinsonism and Parkinson’s disease as they have different recommend
treatments and disease courses. Parkinsonism refers to a clinical syndrome of
bradykinesia, resting tremor, rigidity, postural reflex impairment, shuffling gait and
imbalance, while Parkinson’s disease refers to a type of progressive parkinsonism due
to the loss of dopaminergic neurons in the substantia nigra of the midbrain without an
identifiable cause (Jellinger 1991). The 3 most common disorders that lead to
Parkinsonism are Parkinson’s disease, Progressive Supranuclear Palsy (PSP) and
Multiple System Atrophy (MSA). The most common cause of parkinsonism is
Parkinson’s disease; however, a differential diagnosis is required to differentiate
between the multiple possible causes for parkinsonism (Reich and Savitt 2018).
The current medical procedure to assess Parkinson’s disease is to perform a medical
differential diagnosis, in which the medical practitioner uses several exclusion criteria to
determine if the patient has Parkinson’s disease (Papadakis 2019). Several
characteristic symptoms of Parkinson’s disease can be attributed to other disorders,
such as rigidity and bradykinesia are found in Huntington disease patients, and
myoclonic jerking in Creutzfeldt-Jakob disease patients (Papadakis 2019). However, the
presence of symptoms not characteristic of Parkinson’s disease is used as the
exclusion criteria that indicate the possibility of another disorder to afflict the patient. For
4

example, Creutzfeldt-Jakob disease may present symptoms of parkinsonism, but the
progression is rapid; as well as, Huntington disease could be mistaken for parkinsonism
unless the family history and accompanying dementia are recognized (Papadakis
2019). The Movement Disorder Society (MDS) proposes clinical diagnostic criteria for
Parkinson’s disease, based on 4 main steps (Goldman and Postuma 2014). The first
one is to establish the presence of parkinsonism through visual analysis to recognize
bradykinesia and either rest tremor or rigidity. The second step is to establish the
absence of absolute exclusion criteria to ensure that the parkinsonism is not caused by
another disease. The third step is to identify supportive criteria that are characteristic of
Parkinson’s disease and not usually found in other unrelated courses of parkinsonism;
the most important is a “clear and dramatic beneficial response to dopaminergic
therapy” (Postuma et al. 2015). The fourth and last step is to search for red flags that
might throw uncertainty on the diagnosis; for example, the rapid progression of gait
impairment that would require the use of a wheelchair in the first 5 years of symptoms
onset (Goldman and Postuma 2014). Once the medical practitioner has diagnosed
Parkinson’s disease, the next step is to assign a value in a standardized scale. The two
main scales are the Hoehn Yahr and the Unified Parkinson’s Disease Rating Scale
(UPDRS) (Goetz et al. 2004). The original Hoehn Yahr scale is divided into 5 stages
(Hoehn and Yahr 2011), while the UPDRS has rating scale out of 100. While the Hoehn
Yahr has been criticized due to its focus mainly on the movement complications; the
original version remains widely used nowadays due to its simplicity, and recommended
by the MDS task force when clinical testing has not been performed (Goetz et al. 2004).
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Table 1 presents the original Hoehn Yahr scale for rating the progression of Parkinson’s
disease; which was used in this research project.
Stages

Description

Stage 1

Unilateral involvement only.

Stage 2

Bilateral involvement without impairment of balance.

Stage 3

Mild to moderate bilateral involvement, some postural instability but
physically independent.

Stage 4

Severe disability, still able to walk and to stand unassisted.

Stage 5

Confinement to bed or wheelchair unless aided

Table 1. Original Hoehn Yahr scale for Parkinson’s disease progression rating scale.

However, in spite of the diagnostic criteria proposed by the MDS, it remains a challenge
to have an accurate diagnosis for Parkinson’s disease, as currently the misdiagnose
rate is approximately 18% of the cases (Schrag et al. 2002; Wermuth et al. 2012).
Moreover, in a systematic review of 20 studies from 1988 and 2014, it was found that
during those 25 years, the overall validity of clinical diagnosis for Parkinson’s disease
did not improve significantly. Additionally, the accuracy of clinical diagnosis performed
by movement disorders experts on an initial assessment was found to be at 79.6%
(Rizzo et al. 2016).
The neuropathology of Parkinsonian disorders divides them into two main categories
based on biochemical and structural abnormalities in tau protein and α-synuclein, which
are two major proteins in the central nervous system (Jankovic and Tolosa 2015).
Parkinson’s disease has been traditionally classified as a synucleinopathy (affects αsynuclein); however, the discovery of common genetic variants in the tau gene (MAPT)
in genome-wide association studies of idiopathic Parkinson’s disease shows evidence
6

of a link between Parkinson’s disease and tau protein (Jankovic and Tolosa 2015).
Parkinson’s disease neuropathology is characterized by degeneration of the
nigrostriatal dopaminergic neurons in the substantia nigra (Jankovic and Tolosa 2015).
At this point, synuclein pathology has spread to the midbrain to include basal forebrain
and cortical structures (Jankovic and Tolosa 2015). The degeneration of the
nigrostriatal dopaminergic neurons results in striatal dopamine-deficiency syndrome
that, in turn, is responsible for the classical motor symptoms in Parkinson’s disease
(Jellinger 1991). Moreover, idiopathic Parkinson’s disease is characterized by the
presence of Lewis Bodies – which are abnormal protein aggregate that develop inside
nerve cells (Michael-Titus et al. 2010) – in the nigrostriatal neurons and loss of
neuromelanin pigmentation in the substantia nigra and locus ceruleus (Jankovic and
Tolosa 2015).
While there is no specific cause for the degeneration of said dopaminergic neurons in
the substantia nigra, there are several risk factors that have been directly associated
with Parkinson’s disease. These risk factors include increasing age, male gender, white
race, drinking well water, a diet rich in animal fat, milk and iron, obesity, midlife
constipation, rapid-eye-movement sleep disorder, physical and emotional stress, family
history, rural residence, pesticides, farming, teaching and health care work, and
exposure to metals like iron and manganese (Kasten et al. 2007). Furthermore,
Parkinson’s disease has been found to have 24 different associated genes (Fahn et al.
2011). These include SNCA, MAPT, Parkin, PINK1, LRRK2 and many other gene
mutations. Pathology in patients can vary due to the different gene mutations and even
within single families. Gene mutation can follow a mendelian inheritance as autosomal
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dominant such as SNCA and LRRK2 or autosomal recessive such as Parkin, Pink1 and
DJ-1 (Fahn et al. 2011; Jankovic and Tolosa 2015).
As before mentioned, Parkinson’s disease affects more than 10 million people
worldwide and nearly 1 million people in the US (Marras et al. 2018). Moreover, it has
an estimated crude incidence that ranges from 5 to 20 cases per 100,000 population
per year (Rosati et al. 1980; Rajput et al. 1984; Twelves et al. 2003). Incidence is
defined as the number of new cases of a disease occurring in a specific population
during a given period. As incidence is not affected by survival after diagnosis or by the
migration of affected individuals, it is the best measure of disease frequency (Jankovic
and Tolosa 2015). On the other hand, prevalence reflects both incidence and survival,
as it is defined as the total number of individuals in a population who have the disease
at a specific point in time. The estimated prevalence of Parkinson’s disease in Europe is
between 100 and 200 cases per 100,000 population (Kasten et al. 2007) and in North
America 572 per 100,000 (Marras et al. 2018). Moreover, comparison of prevalence
studies worldwide indicate that Parkinson’s disease might be more common in the
developed world (Kasten et al. 2007); however, due to the methodological differences,
such as age distribution, the results might be confounded. Nevertheless, it is clear that
the prevalence rises exponentially after the age of 50 (Kasten et al. 2007).
Sensor-based assessments
Since gait is a coordinated action between the nervous system and the musculoskeletal
system, it makes gait a reliable indicator of neurodegenerative diseases (Ortells et al.
2018); therefore, the interest of implementing computer systems in the analysis of gait
patterns to aid in the diagnosis of neurodegenerative diseases. An approach taken to
8

develop computer-based systems to aid in the diagnosis and monitoring of Parkinson’s
disease is the sensor-based assessment. Several systems have been developed with
successful results, with different approaches between older and recent systems. Earlier
versions involve more invasive wearable sensors strapped to upper or lower extremities
(Keijsers et al. 2006; Bächlin et al. 2009; Pansera et al. 2009; Patel et al. 2009; Cancela
et al. 2010). Contrastingly, more recent developments have diminished the
invasiveness of the sensors and implemented a pair of sensors attached to the ankles
or shoes (Moore et al. 2008; Barth et al. 2011; Raccagni et al. 2018). Moreover, some
have focused on the detection of gait freezing, which is a common cause of falls in
advanced Parkinson’s, in order to monitor the patient and prevent falls that can later
lead to lethal ailments, such as internal bleeding (Moore et al. 2008; Bächlin et al.
2009). Most of the sensor-based approaches use accelerometers, gyroscopes, EKG
measurements or a combination of these in order to track and analyze a variety of
movement-related features and find recognizable differences in the patterns (Keijsers et
al. 2006; Rissanen et al. 2008; Bächlin et al. 2009; Pansera et al. 2009; Patel et al.
2009; Cancela et al. 2010; LeMoyne et al. 2010, 2010). The tracking of movement
patterns other than gait has also shown promising results (Keijsers et al. 2006;
Rissanen et al. 2008; LeMoyne et al. 2010; Eskofier et al. 2016). Furthermore, the
implementation of deep learning algorithms – a subset of machine learning in artificial
intelligence – in sensor-based movement assessment has shown improved results
compared to machine learning algorithms previously used (Eskofier et al. 2016). It is
important to highlight that while many of the systems cited are specialized in detecting
or monitoring Parkinson’s disease movement abnormalities, research has also been
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performed to analyze the differences between gait patterns of other causes of
parkinsonism that can be misidentified as Parkinson’s disease (Raccagni et al. 2018),
such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). This
is relevant as Parkinson’s disease has been shown to be misdiagnosed in
approximately 18% of the cases (Schrag et al. 2002; Wermuth et al. 2012).
Computer-based vision systems assessments
Computer vision systems can gain high-level understanding from digital images and
videos. The implementation of computer vision systems to track gait patterns is a field
that has grown significantly in the last decade as gait is unique for every person and the
visual assessment can be automated with a computer. In addition, computer vision
analysis is a non-invasive, non-intrusive measurement since the subject does not need
to behave in a certain way (Lee et al. 2014). Moreover, cameras and video processing
software have improved enough to track and analyze biomechanical data. For these
reasons, the implementation of computer vision systems as a diagnostic and treatment
supportive tool has gained interest in the scientific and medical community. Some
systems tend to need specialized environments and computationally expensive
processes (Green et al. 2000; Lee et al. 2008; Cho et al. 2009), while less sophisticated
vision devices, such as Microsoft Kinect, have shown accurate measurements on a
variety of gait parameters (Rocha et al. 2015; Xu et al. 2015) and some other devices
have used computationally inexpensive calculations (Khan et al. 2013).
Most computer-based vision assessments use consumer standard cameras to record
the movements of Parkinson’s disease patients. The main differences appear in the
image analysis methods and algorithm to determine if the subject has Parkinson’s
10

disease. Dr. Kahn and his team in Motion Cue Analysis for Parkinsonian Gait
Recognition (Khan et al. 2013) provide a clear vision-based algorithm for parkinsonian
gait recognition. First, a recording of the subject is made, then a background subtraction
is applied to differentiate the pixels from the subject and the background. Posteriorly, a
noise-filtering technique is applied and then the silhouette is isolated. Afterward, a
skeleton is made by applying a model fitting to distinguish the head, torso and leg
segments. Finally, motion cues are extracted and compared to an imaginary perfect gait
to determine if the subject presents normal or parkinsonian gait.
Gait analysis methods
Different analysis techniques are used for the gait parameters. The most prevalent are
Linear discriminant Analysis (LDA) (Green et al. 2000; Cho et al. 2009) and SupportVector Machine (SVM) (Bauckhage et al. 2009; Khan et al. 2013). Linear discriminant
analysis is a method commonly used in machine learning for the classification of one or
more groups in a sample by using features related to the groups. Support Vector
Machine works similarly to LDA with the main difference that the SVM focuses on the
points that are difficult to classify giving more weight to those. Meanwhile LDA assumes
that data is normally distributed. SVM finds a hyperplane that divides the sample into
groups by optimizing the distance between the data points that are close to the
boundary. Both approaches are less computationally expensive compared to neural
networks and other deep learning techniques. Moreover, a more recent approach used
a cloud platform-based web service to perform a classification between normal and
abnormal gait (Nieto-Hidalgo et al. 2018). A cloud platform is convenient as it
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eliminates the need for on-site data processing, and it optimizes the need for
computational resources.
Frontal versus sagittal
Another relevant difference within the published research is the use of frontal versus
sagittal image analysis. In frontal analysis, the patient walks straight to and away from
the camera, while in sagittal analysis the subject walks on a straight line perpendicular
to the vision field of the camera. Frontal analysis is advantageous due to the reduction
of space for the patient to walk. However, as shown by Nieto-Hidalgo and his team, the
sagittal approach proved to be more accurate (Nieto-Hidalgo et al. 2018).
Kinect implementation
In previous research, Microsoft’s Kinect has been implemented for Parkinson’s disease
detection. Rocha and her team were able to develop a system based on Kinect v2 for
Parkinson’s Disease Assessment (Rocha et al. 2015). The data evaluated showed that
96% of gait parameters were statistically significant to make a distinction between
controls and Parkinson’s subjects. Therefore, they concluded that the gait analysis
provided by Kinect v2 was valuable as a supportive method for assessing Parkinson’s
disease in a clinical setting. It is important to recognize the advantages provided by the
implementation of the Kinect, which are the computational inexpensive processing and
the reduction of the constraints in the environment while reducing noise in the image
processing at the same time.
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Chapter II: Materials and Methods
The subject’s gait was recorded using a Microsoft Kinect v2 and Microsoft Kinect Azure
while the subject walked unaided over an unobstructed 10 meters walkway. The Kinects
were placed perpendicular to the subject’s path (sagittal view or side view). Recordings
by the beforementioned devices were limited to joint tracking and calculation between
the angles of the specific joints. Two programs were developed, as each one of the
sensors uses a different language. The program used for Microsoft’s Kinect for Xbox
One was a modified version provided by Guillermo Hernandez from a previous project;
while the program used for Microsoft Azure Kinect was a modified version of Microsoft’s
Azure Kinect Samples, specifically a modified version of the simple_sample project
(Microsoft 2019). The 3D position of the body joints was provided by the sensors and in
the same programs, the angles between the joints were calculated and recorded over
time. The joints tracked by Kinect Azure and Kinect v2 are shown in figures 1 and 2
respectively. The angles of the joints were calculated using the following formula, where
a, b, c are the 3D vectors of the corresponding joints for the angles.
𝐴=𝑎−𝑏
𝐵 =𝑐−𝑏
𝐴
𝐵
180
)∗
180 − acos ( ∗
|𝐴| |𝐵|
𝜋
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Figure 1. Body joints tracked by Kinect Azure. Retrieved
from: (Microsoft 2019b)

Figure 2. Retrieved from:(Microsoft 2018)

In this research project, seven different angles were calculated, as shown in table 1.
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Angle name

Joints

Right knee angle

Right ankle, Right knee, Right hip

Inner torso angle

Pelvis, Spine Navel, Spine chest

Wide torso angle

Neck, Spine navel, Pelvis

Right elbow angle

Right shoulder, Right elbow, Right wrist

Neck angle

Head, Neck, Spine chest

Stride angle

Pelvis, Right ankle, Left Ankle

Right arm swing angle

Right shoulder, pelvis, right wrist

Table 2. Angles and their corresponding joints used in the calculations

Parkinson’s patients were recruited from Clinica Parkinson Puebla, which is a
Parkinson’s clinic in Puebla, Mexico. Subjects recruited were older than 18 years old
(male or female) with a Parkinson’s disease diagnosis by a neurologist. 12 previously
diagnosed Parkinson’s patients accepted to participate in the research. These patients
were diagnosed by the head neurologist of the Clinica Parkinson Puebla, Dr. EnriquezCoronel. Parkinson’s patients ranged in the Hoehn Yahr scale from levels 2 to 4. All
patients were under treatment; however, none have gone under deep brain stimulation
surgery (DBS). Deep brain stimulation is a common treatment for Parkinson’s disease
patients as it shows improvement of all cardinal motor symptoms with sustained longterm benefits, and significant improvement of quality of life when compared with best
medical treatment (Groiss et al. 2009). Therefore, patients with DBS would show
reduced symptoms; thus, being impractical for this experiment. Ages ranged from 52 to
83 years old. Moreover, 13 controls were recruited from the University of Mississippi
student, faculty and staff population. Ages ranged from 21 to 55 years old.
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Parkinson's Patients

Controls

Male

Female

Male

Female

Participants

2

10

8

5

Age range

52-76

62-83

23-55

21-24

Table 3. Distribution of patients and controls by gender and age range for each group.

Hoehn Yahr Scale

Male

Female

1

-

-

2

-

3

3

2

5

4

-

2

5

Not able to walk unless aided

Table 4. Distribution of Parkinson’s patients for the Hoehn Yahr scale. Patients on level 5 were not included as those patients
cannot walk unless aided.

1-3 measurements were taken for each Parkinson patient depending on gait difficulties
of the subject; additionally, 3 measurements for each control were taken to ensure that
at least one measurement was available for analysis, as sensors failed often to record
the data resulting in empty files.
A linear support vector machine (SVM) was implemented in R for the classification of
Parkinson’s patients versus controls. The angles provided by the first two programs
were read into the R program, and the standard deviation for each angle per subject
was calculated. The mean and median of the standard deviations for the angles of
Parkinson’s patients and controls were calculated and compared to see which angles
had a larger difference and thus expected to be better classifiers. Afterward, the

16

standard deviations of each angle per patient were fed to the SVM as features for
classification.
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Chapter III: Results
As the Kinect V2 sensor had problems to record the data often resulting in empty files,
the data obtained from the Kinect V2 sensor was not used in this analysis. All the
following results are based on the Azure Kinect sensor recordings.
In order to have a better understanding of what features could work best for the SVM
the medians and means of each angle for all Parkinson’s patients and controls where
calculated, as it can be seen in table 5.
Angle

Median
SD of
PD
Median
SD of
controls
Mean
SD of
PD
Mean
SD of
controls

Right
knee
angle

Inner
torso
angle

Wide
torso
angle

Right
elbow
angle

Neck
angle

Stride
angle

Right arm
swing
angle

11.60

1.928

2.333

12.59

1.920

9.370

6.539

17.68

1.816

2.341

11.77

1.929

12.42

6.577

17.75

1.874

2.535

13.84

1.881

13.30

7.253

11.39

2.012

2.506

14.08

1.749

11.62

7.484

Table 5. Medians and means of standard deviation per angle for Parkinson’s patients (PD) and controls.

Posteriorly, the difference for the median and mean of the standard deviation between
Parkinson’s patients and controls is shown in tables 6 and 7 respectively.
Angle

Median SD

Right
knee
angle
6.079

Inner
torso
angle
0.1126

Wide
torso
angle
0.0076

Right
elbow
angle
0.8146

Neck
angle

Stride
angle

0.0086

3.0555

Right arm
swing
angle
0.0377

Table 6. The difference of median standard deviation between PD patients and controls per angle.

Angle

Mean SD

Right
knee
angle
6.360

Inner
torso
angle
0.1383

Wide
torso
angle
0.0294

Right
elbow
angle
0.2310

Neck
angle

Stride
angle

0.1319

1.682

Table 7. The difference of mean standard deviation between PD patients and controls per angle.
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Right arm
swing
angle
0.2304

As seen in the tables, the right knee angle showed the highest difference for both mean
and median. While the stride angle also showed a high difference in the median, the
difference was much lower in the mean. This could probably happen due to median
being less susceptible to outliers compared to the mean. Furthermore, the right elbow
angle showed a lower difference in the median compared to the previous two angles;
however, it showed to be a better classifier than the stride angle. The support vector
machine (SVM) showed better results at classifying the subjects when the standard
deviation from the right knee angle and the right elbow angle were used as shown in
figure 3. When the right knee angle and right elbow angle standard deviations were
used as features for the SVM, it was able to classify the Parkinson’s patients with an
86% accuracy. Moreover, the SVM was fitted with the right knee angle and stride angle,
as the stride angle showed a high difference in the median standard deviation between
Parkinson’s patients and controls. The SVM classification plot is shown in figure 4.
However, the accuracy for the SVM fitted with right knee angle and stride angle
standard deviations was lower, achieving an 83.7%, as seen in figure 5. The accuracy
of the SVM was calculated using the following equation.
𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 + 𝑇𝑟𝑢𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒
𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 + 𝑇𝑟𝑢𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒 + 𝐹𝑎𝑙𝑠𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 + 𝐹𝑎𝑙𝑠𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒
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Figure 3. SVM classification plot for right knee angle standard deviation and right elbow angle standard deviation. Blue points
represent the Parkinson’s patients, red points represent controls. Points in a square represent support points. The solid black line
represents the decision boundary. Dashed lines represent the upper and lower margin of the decision boundary.
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Figure 4. SVM classification plot for right knee angle standard deviation and stride angle standard deviation. Blue points represent
the Parkinson’s patients, red points represent controls. Points in a square represent support points. The solid black line represents
the decision boundary. Dashed lines represent the upper and lower margin of the decision boundary.

Furthermore, to see if an improvement in accuracy could be achieved, the same SVM
was fitted with recordings from Parkinson’s disease patients that were diagnosed with a
level equal or greater than 3 in the Hoehn Yahr scale. As can be seen in figure 6, the
accuracy of the SVM to classify the data increased to 90%, by just misclassifying 1 out
of 9 Parkinson’s patients and the previous 3 controls.
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Figure 5. SVM classification plot for right knee angle standard deviation and right elbow angle standard deviation with recordings
only from patients that had a Hoehn Yahr level of ≥3. Blue points represent the Parkinson’s patients, red points represent controls.
Points in a square represent support points. The solid black line represents the decision boundary. Dashed lines represent the
upper and lower margin of the decision boundary.
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Chapter IV: Discussion
As Parkinson’s disease is the second most common neurodegenerative disorder (Reich
and Savitt 2018) and it has no identifiable cause, it is a public health concern to find
more effective methods to diagnose and monitor the disease. As presented in this
thesis, several different approaches have been taken in order to develop systems that
can aid doctors in their diagnosis and monitor the disease progression. While in more
recent developments the size of the sensors has been reduced and the placement has
been in less uncomfortable areas, the sensor-based assessments remain invasive.
Computer vision systems show a significant advantage over the sensor-based
assessment, as these are not invasive and have similar effectiveness in detecting
parkinsonian gait patterns. Moreover, computer-vision systems can be computationally
expensive, which can limit their implementation in the clinics, thus the importance of
developing systems that are less computationally expensive.
It is interesting that only 3 of the 7 angles measured were significant for the SVM
classification, and that it was mainly the right knee angle feature that allowed the SVM
to classify the subjects. While in this thesis the patient population was small, the
accuracy for classifying the subjects was slightly higher (86% vs ~82%) than the current
subjective assessment, which currently has a ~18% misdiagnose rate (Schrag et al.
2002; Wermuth et al. 2012). Furthermore, it is important to notice that when Parkinson’s
patients’ recordings were limited to patients with level 3 or higher, the accuracy of the
SVM classification increased to 90%.
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Challenges
Despite the promising results from this system, there are some challenges for the
implementation in a clinic setting. Some patients might feel uncomfortable with a
camera recording them during their visit to the doctor. Furthermore, a key challenge is
that most of the systems analyzed in current literature and the one implemented in this
thesis are efficient at detecting the parkinsonian gait; however, less research has been
performed in order to differentiate between the diverse causes of parkinsonian gait, as it
can not only be caused by idiopathic Parkinson’s disease but atypical parkinsonism
disorders such as MSA and PSP. Moreover, even Parkinson’s disease has been found
to have 24 different associated genes (Fahn et al. 2011); therefore, further research is
needed to have a better understanding of the disease; which consequently will allow
having better diagnostics and treatments.
A larger and more diverse sample for Parkinson's disease patients and controls would
be desired to increase and test the accuracy of the SVM classification system; however,
it is difficult to recruit Parkinson’s disease patients that can walk unaided and show
enough symptoms to have a Parkinson’s disease diagnosis.
At the same time, a relevant challenge is that, as before mentioned, the misdiagnose
rate is ~18%; thus; putting in doubt the validity of the data used to perform the analysis.
In all the literature analyzed in this thesis; it is assumed that the patients have been
correctly diagnosed, and, as in this research project, patients are recruited from highly
experienced neurologists that should have very low misdiagnose rates.
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Future perspectives
These challenges should be encouraging to the scientific and medical community to
continue developing systems that aid medical practitioners in their diagnosis and
understanding of the disease course, as well as improve life quality for patients. Further
research needs to be performed to develop more accurate and precise systems. A more
complete assessment could include a combination of approaches for the diagnosis of
Parkinson's disease, including genetic profiles and non-motor symptoms. This type of
future assessment could be very helpful in the analysis of the disease’s course and
decrease the misdiagnose rate. Furthermore, the implementation of computationally
inexpensive computer vision systems, such as the one presented in this thesis, in the
clinical setting could be incredibly helpful as a supportive tool in the diagnosis of
Parkinson’s disease by adding a quantitative component to the diagnosis as well as,
with a very large sample, be able to classify the Parkinson’s disease progress into the 5
main stages of the Hoehn Yahr scale. Moreover, future research could develop systems
that detect subtle movements imperceptible to some medical practitioners; this could
lead to opportune treatments to delay the onset of motor symptoms.
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